Ideaya Biosciences saw its stock move higher in morning trading after the company said it had enrolled the first patient in a Phase 1/2 clinical trial evaluating the combined use of IDE892 and IDE397 in patients with MTAP-deleted solid tumors. The company described IDE892 as its investigational PRMT5 inhibitor and IDE397 as its investigational MAT2A inhibitor. The trial population named by the company includes patients with non-small cell lung cancer and pancreatic cancer.
The enrollment represents the pipeline milestone Ideaya had publicly targeted for mid-2026 and indicates that the combination arm of the study is now active following earlier monotherapy dose escalation work. Company statements say the combination evaluation follows those initial dose-escalation efforts and that the first-patient enrollment is the first concrete sign that the dual-agent portion of the study is underway.
Investors have responded to the clinical update in part because of the scientific rationale presented by the company. According to Ideaya, MTAP deletion is present in roughly 15% of all solid tumors and can be found in as many as 40% of pancreatic cancer cases. The company points to a synthetic lethality approach in which simultaneous inhibition of PRMT5 and MAT2A is intended to exploit a vulnerability created by MTAP loss.
Preclinical data cited by the company reportedly showed that the combination of IDE892 and IDE397 produced durable, complete tumor responses in MTAP-deleted models at dose levels below those required for activity when either agent was used alone. Ideaya also noted that no approved therapies currently exist specifically for this MTAP-deleted patient population.
Adding to the program-level developments, Ideaya recently announced a clinical collaboration with Roche to evaluate IDE892 alongside a pan-RAS inhibitor in MTAP-deleted pancreatic cancer, broadening the potential scope of the company’s development efforts in this biomarker-defined group.
The market environment today was favorable for risk assets, with the S&P 500 advancing 1.5% and the NASDAQ climbing 2.3%, a session that lifted growth-oriented biotech names. Analysts tracked in the market continue to express constructive views on Ideaya: the consensus price target sits well above the level at which the shares were trading, and multiple Buy and Outperform ratings remain in place, suggesting market participants regard the clinical news as a meaningful de-risking event rather than a routine update.
In trading, Ideaya shares reached a session high of $30.65, moving above the prior close of $28.98. The stock had risen nearly 4.8% in morning trading on the announcement.
What this means
- The first-patient enrollment launches the combination arm of the Phase 1/2 trial after monotherapy dose-escalation work.
- The program targets a biomarker-defined population where MTAP deletion creates a theoretical therapeutic vulnerability for dual PRMT5 and MAT2A inhibition.
- A separate collaboration with Roche expands clinical evaluation of IDE892 in combination with a pan-RAS inhibitor for MTAP-deleted pancreatic cancer.
Further context and limitations
The company has emphasized preclinical results demonstrating durable, complete responses in MTAP-deleted models and noted the absence of approved therapies for this subgroup. The current update confirms the initiation of the combination arm but does not provide patient-level outcome data or additional timing on enrollment cadence beyond the mid-2026 milestone the company had publicly targeted.